Renal Doppler to Predict Acute Kidney Injury (AKI) in ARDS Patients. (RED-AKI Study)
NCT ID: NCT06302192
Last Updated: 2024-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
164 participants
OBSERVATIONAL
2024-04-01
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* PRIMARY AIM: To describe the capability of IRVF demodulation at diagnosis of ARDS to predict development of AKI within 7 days from the ARDS onset
* SECONDARY AIMS: A)Describe the capability of IRVF demodulation or pattern of IRVF (continuous, pulsatility, biphasic, monophasic) to predict development of AKI within 14 days from the ARDS onset. B) To describe the RD parameters and VexUS in the AKI and no AKI patients over time. C) Describe the impact of invasive mechanical ventilation (IMV) on the intrarenal venous congestion and VexUS., D) Evaluation of effect of CRRT on IRVF pattern, VexUS and parameters. E) Describe the feasibility of renal doppler to assess IRVF in critically ill respiratory patients. F) Evaluate the incidence of AKD and CKD Participants will Adult patients with diagnosis of ARDS admitted to intensive care unit and undergoing invasive mechanical ventilation
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Doppler-based Renal Resistive Index in Assessing Renal Dysfunction Reversibility in ICU Patients
NCT02355314
Role of Renal Artery Doppler in Critically Ill Children With Acute Kidney Injury
NCT06202326
Predictive Value of Doppler RSI for Prediction of AKI in Septic Patients in ICU
NCT04426032
Carotid Doppler and IVC Measurements for Volume Guided Management in Acute Kidney Injury Patients
NCT05938049
Doppler Ultrasound for Prediction of Reversibility of Acute Kidney Injury in Septic ICU Patients
NCT03597074
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ARDS+AKI
according to the clinical practice Reanl doppler and VeXUS score will be performed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Critically ill patients admitted to intensive care unit with a diagnosis of ARDS according to Berlino criteria
* Beginning of IMV less than 48 hours or Clinical decision to begin IMV.
* Life expectancy \> 24 hours
* Informed consent signed
Exclusion Criteria
* AKI prior to the onset of ARDS
* Chronic respiratory failure due to chronic respiratory diseases
* Chronic renal disease (CKD stage ≥ 2) and any ureteral obstruction. Definition of CKD patient is according to the latest guideline KDIGO
* Chronic Heart Failure
* Chronic liver disease
* Major trauma in the past 3 months
* Major surgery in the past 3 months
* Smoking and Alcohol drinking
* BMI ≥ 35
* Patients needing of VV-ECMO and VA-ECMO
* Beginning of positive pressure ventilation more than 48 hours (invasive or no invasive)
* Life expectancy \<24 hours
* Cardio Circulatory Arrest
* Neoplasm in chemotherapy/radiotherapy
* Do Not Resuscitate or Comfort Measures
* Pregnancy at ICU admission
* Refused Informed Consent by the patient or surrogate decision-maker
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Policlinico Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giacomo Grasselli
Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.